2. ! "
# $ ! %! & ' (
) *+
) ! , * -
.
.
! ! ! !
.

3. / 0 '
1 ! ! /
#
#
) ! '!
2
*
+
3

7. ! , -

10. Current status:
Pre-erythrocytic vaccines
• RTS,S (U.S. Army & GlaxoSmithKline)
–Recombinant CSP combined with hepatitis
B surface antigen
– Immune boosting agents (adjuvant)
• AS02A: QS21, monophosporyl lipid A

11. 4 . / 5
4 .
' %!
6.766 8 9
! / :;<
/ 9=<
! 8=
3 1 6779. 677;

13. 8 6 : 9 ; > ? = @ 87 88 86 8: 89 8; 8>A B/
8@ C
D
5 8 /5 8 / 889696
! 8
'! !
1
# > D 8>99 ,E F*-. 8>@8 ,CF -. 8>@@
, FD-. 8?77 ,DF -. 8?78 ,G F4-. 8?8> ,1F5-
3 ' 8@ B ' B
.

14. 896 ' +
# ! ! ' H 4 3 ) !
4
&! 4 . ,3 763-
# ! ! ' G + C A
H . ! 8 2
6 !
// 889696

15. Bandiagara Malaria Project
• Started 1997
• University of Bamako / Faculty of Medicine
– Malaria Research & Training Center
• University of Maryland
– Center for Vaccine Development
• US National Institutes of Health
• 20 scientific papers published
• 2 malaria vaccine trials completed

27. 8 +8 +
6 ! C
8 9
8 '
4 ! + +
) .
' 4 .

28. Malaria vaccine AMAMalaria vaccine AMA--11
• P. falciparum apical membrane antigen-1
• Expressed on merozoite surface,
involved in erythrocyte invasion
• Antibodies block invasion of merozoites
into erythrocytes

29. 3 3 8
3 3 8 '
+
! !

30. 3 33 3 8 +8 +
8 6
8 >
3 3 8 '
8 677>
6 677?

31. ! !
' "
# !
# !
I I +!
D3 "
1 . !

32. / !
1 '
4 .
A
!
3 '
;
)
3 ! ' !
# A . ) . .

33. B
3 0 !
C 1 B
D *
J ! 3B
4 ' A!
1 4
1 !
1 !
1 A
* !
4
0 ' ! '
! '
3' ! C
3 G !
C
3' ! &
A
D)K )
3' D
1 K
H 43)4
G K
3
* 3
J 1
G C
3 1
3
D)K 5)
D)K A
!
D)K D783)=;:9>
D)K ) ) 4
3) , -
H 43)4 , -
G C , &! -